Formycon and its licensing partner, Klinge Biopharma GmbH ("Klinge"), announced Thursday, June 29, 2023 that an aBLA for FYB203, a biosimilar candidate for Eylea® (aflibercept), had been submitted to the FDA and that a decision on acceptance is expected within 60 days. As we previously reported, Coherus BioSciences Inc. agreed in January to acquire the exclusive commercialization rights to FYB203 from Klinge. And per our prior reports, Formycon conducted its Phase III trial of FYB203 in neovascular age-related macular degeneration (AMD).